Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

UB-VV100

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Umoja Biopharma

Drug class:

CD19-targeted CAR-T immunotherapy

Related drugs:

‹

axicabtagene ciloleucel (24)

lisocabtagene maraleucel (23)

tisagenlecleucel-T (15)

brexucabtagene autoleucel (4)

relmacabtagene autoleucel (2)

obecabtagene autoleucel (1)

CAR-T19/CAR-T22 immunotherapy (1)

varnimcabtagene autoleucel (1)

Anti-CD19 CAR-T (0)

Anti-CD19-CAR (0)

Anti-CD19/CD20/CD22 CAR T-Cells (0)

Autologous CAR-T cells (0)

CAR-20/19-T Cells (0)

CAR-T CD19/CD20/CD22/CD30 (0)

CAR19T2 T cells (0)

CAR20.19.22 T (0)

CARCIK-CD19 (0)

CART-138/BCMA/19/more (0)

CD19 CAR T cells (0)

CD19 UCART cells (0)

CD19 and CD22 targeted prime CAR-T (0)

CD19 targeted CAR-T (0)

CD19-7×19 CAR-T (0)

CD19-CAR-DNT (0)

CD19-CAR-T2 cells (0)

CD19-CAR.CD45RA- negative T-cells (0)

CD19-CAR_Lenti T cells (0)

CD19-CD22 CAR-T (0)

CD19-CD34 CAR transduced T cells (0)

CD19-CD34t metabolically programmed CAR transduced T-cells (0)

CD19-PD1-CART cell (0)

CD19-targeted CAR-T cells (0)

CD19/BAFF-R dual CAR T (0)

CD19/BCMA targeted CAR T-cells (0)

CD19/CD20 CAR T-cells (0)

CD19/CD22 CAR T-cells (0)

CD19/CD22 CAR-T cell therapy (0)

CD19/CD22 chimeric antigen receptor T cell (0)

CD19/CD22 dual-target CAR-T (0)

CD19/NKG2DL CAR-T Therapeutic (0)

CD19CAR/virus specific T cell therapy (0)

CD19x22 CAR T (0)

CD20-CD19 cCAR T cells (0)

CD22/CD19 CAR T (0)

CLBR001/SWI019 (0)

CMV/CD19 bi-Specific CAR T (0)

CTA30X UCAR-T (0)

DDCAR-CD19 T-cells (0)

EGFRt/19-28z/4-1BBL CAR T cells (0)

IM19 CAR-T cells (0)

MB-CAR-T19-22 (0)

MB-CART 19.1 (0)

RPM CD19-mbIL15-CAR-T cells (0)

anbalcabtagene autoleucel (0)

SCRI-CAR19x22v2 (0)

SCRI-huCAR19v1 (0)

SCRI-huCAR19v2 (0)

SNUH-CD19-CAR-T (0)

STK-009/SYNCAR-001 (0)

Senl_H19x22P (0)

ThisCART19A (0)

UCD19 CAR T Cells (0)

XYF19 CAR-T cells (0)

inaticabtagene autoleucel (0)

alloCART-19 cell therapy (0)

anti-CD19 CAR-T cell therapy (0)

anti-CD19 CAR-T cell therapy (0)

anti-CD19 CAR-T therapy (0)

anti-CD19 DASH CAR-T (0)

anti-CD19-CAR (0)

anti-CD19-CAR γδT (0)

anti-CD19/CD22 CAR-T cells (0)

autologous 3rd generation CD19-targeting CAR T cell therapy (0)

autologous TriCAR T (0)

human derived (0)

huCART19-IL18 (0)

human anti CD19 CAR-T cells (0)

humanized CD19 CAR-T cell therapy (0)

iC9-CAR19 cells (0)

multi-CAR-T cell therapy (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

murine CD19 CAR-T cell therapy (0)

murine autologous anti-CD19 CART cells (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

MB-CART2019.1 (0)

›

almost2years

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. (PubMed, J Immunother Cancer)

These findings demonstrate that UB-VV100 generates functional CAR T cells in vivo, which could expand patient access to CAR T technology in both hematological and solid tumors without the need for ex vivo cell manufacturing.

almost 2 years ago

Preclinical • Journal • CAR T-Cell Therapy

|

CD19 (CD19 Molecule) • CD34 (CD34 molecule) • IL15 (Interleukin 15)

|

sirolimus • UB-VV100